235 related articles for article (PubMed ID: 28847226)
1. Dynamic Risk Stratification in Stage I Papillary Thyroid Cancer Patients Younger Than 45 Years of Age.
Sung TY; Cho JW; Lee YM; Lee YH; Kwon H; Jeon MJ; Kim WG; Choi YJ; Song DE; Chung KW; Yoon JH; Hong SJ
Thyroid; 2017 Nov; 27(11):1400-1407. PubMed ID: 28847226
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
3. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
4. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm.
Lee YM; Cho JW; Hong SJ; Yoon JH
J Surg Oncol; 2018 Sep; 118(4):636-643. PubMed ID: 30114339
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
6. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
7. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
8. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up.
Grogan RH; Kaplan SP; Cao H; Weiss RE; Degroot LJ; Simon CA; Embia OM; Angelos P; Kaplan EL; Schechter RB
Surgery; 2013 Dec; 154(6):1436-46; discussion 1446-7. PubMed ID: 24075674
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
Tavarelli M; Sarfati J; Chereau N; Tissier F; Golmard JL; Ghander C; Lussey-Lepoutre C; Trésallet C; Menegaux F; Leenhardt L; Buffet C
Thyroid; 2017 Jun; 27(6):778-786. PubMed ID: 28351220
[TBL] [Abstract][Full Text] [Related]
10. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
Ebina A; Sugitani I; Fujimoto Y; Yamada K
Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
13. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
14. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
15. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
[TBL] [Abstract][Full Text] [Related]
16. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
17. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
18. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
19. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.
Yildirim E
J Am Coll Surg; 2005 Mar; 200(3):378-92. PubMed ID: 15737848
[TBL] [Abstract][Full Text] [Related]
20. Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting.
Kwon H; Jeon MJ; Kim WG; Park S; Kim M; Kim TY; Han M; Song DE; Sung TY; Yoon JH; Hong SJ; Ryu JS; Shong YK; Kim WB
Ann Surg Oncol; 2017 Sep; 24(9):2596-2602. PubMed ID: 28600731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
